Pacibekitug Biosimilar Monoclonal Antibody (IL-6) for Research

Cat No.: GMP-Bios-INN-1324

Anti-IL6 therapeutic antibody (Pre-made Pacibekitug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Pacibekitug (development code PF-04236921/TOUR-006) is a monoclonal antibody targeting interleukin-6 (IL6). It is developed by Pfizer and Tourmaline Bio for cardiovascular disorders and Graves ophthalmopathy. It is in Phase II clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1324-1mg 1mg 3090
GMP-Bios-INN-1324-10mg 10mg
GMP-Bios-INN-1324-100mg 100mg
GMP-Bios-INN-1324-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Pacibekitug biosimilar, Whole mAb, Anti-IL6 Antibody: Anti-BSF-2/BSF2/CDF/HGF therapeutic antibody
INN Name Pacibekitug
Target IL6
Format Whole mAb
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G2
VD LC Kappa
Highest_Clin_Trial (Jan '20) Phase-II
Est. Status Active
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2024
Year Recommended 2024
Companies Pfizer;Tourmaline Bio
Conditions Approved na
Conditions Active Cardiovascular disorders;Graves ophthalmopathy;Kidney disorders
Conditions Discontinued Crohn's disease;Rheumatoid arthritis;Systemic lupus erythematosus
Production na
Development Tech na